1. Which of the following is the most correct statement regarding expected outcomes for treatment of relapsed, refractory follicular non-Hodgkin lymphoma?

2. Which of the following agents administered in combination with lenalidomide to treat follicular non-Hodgkin lymphoma has demonstrated efficacy and a reasonable safety profile?

3. Which of the following is a targeted agent for follicular non-Hodgkin lymphoma with an activating mutation of EZH2?

« Return to Activity